Articles On Telix Pharmaceuticals (ASX:TLX)

Telix (ASX:TLX) says olaratumab, an antibody licensed from Eli Lilly, has demonstrated proof-of-concept in a preclinical study investigating its delivery of diagnostic and therapeutic radiation to tumours.

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March...

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Comp...

The S&P/ASX 200 Index (ASX: XJO) ended the week on a high, rising 0.51% to finish the session at 7,361.6 points – its highest close since early March. That also leaves it 1.98% higher week-on-week. It followed a strong session over o...

MELBOURNE, Australia, April 11, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a...

The S&P/ASX 200 Index (ASX: XJO) put on a rocky performance on Wednesday, eventually closing the session 0.02% higher at 7,237.2 points. The fall came as Reserve Bank of Australia (RBA) governor Philip Lowe addressed the National Pres...

In a recent memo to investors, Wilsons equity strategist Rob Crookston pointed out how there are many similarities between 2023 and 2019. In both those years the economy was slowing. In 2019, the Reserve Bank of Australia and US Federal re...

The ASX swung into positive after the release of monthly CPI data Australia’s inflation has declined to 6.8% in February from 7.4% in January SBF allegedly bribed Chinese officials with $40 million in cryptos   Local shares traded lower b...

ShareCafeGains from Energy and Materials boost ASX: Aus shares close 1% higher by Peter Milios   At the closing bell, the S&P/ASX 200 was 1.04 per cent higher at 7,034.10, with the Energy sector leading the gains and surging 4.1 per cen...

The S&P/ASX 200 Index (ASX: XJO) started the week out on the right foot today, lifting 0.1% to close Monday’s session at 6,962 points. The major news on investors’ minds this morning came from overseas, however. Stock in Germany’...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

The medical imaging market size globally is forecast to reach $68.8 Billion by 2030 Several ASX health imaging stocks are establishing strong footholds and niches in sector Micro-X branching out from the medical sphere with its bomb detect...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development. -Brokers retain bullish commentary on Telix Pharmaceuticals -Jarden expects positive operational...

Saturday March 11 was a typical balmy autumnal afternoon in Melbourne, but Neuren (ASX:NEU) chief Jon Pilcher was despondent as he awaited news from the company’s US partner Acadia on whether the US Food and Drug Administration (FDA) had ap...

ASX health stocks fall 1.5% in the past five days, broader markets fall on global banking concerns Neuren Pharmaceuticals has soared 60% after FDA approves its drug for Rett’s syndrome  Antisense starts chronic monkey toxicology study of A...

The ASX 50 drops 1.50% and ASX 200 loses 1.46% ABS say unemployment rate fell to 3.5% for February following two months of consecutive falls Labour force data is one of four economic data points the RBA uses when looking at rate hikes   A...

Telix Pharmaceuticals (TLX) has landed US FDA approval to image patients with metastatic prostate cancer with its Illuccix imaging agent The FDA has approved a supplementary new drug application (sNDA) for Illuccix, enabling TLX to ident...

Telix Pharma gets FDA approval Prescient shows good data from Phase 1b clinical trial Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas   Telix Pharma (ASX:TLX) announced the US FDA has a...

MELBOURNE, Australia, March 14, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girent...

The S&P/ASX 200 Index (ASX: XJO) regained some of its Monday losses today, closing 0.47% higher at 7,258.4 points. Leading the charge were energy stocks, with the S&P/ASX 200 Energy Index (ASX: XEJ) gaining 1.5% with the Woodside E...

The final day of earnings season has seen a number of ASX 200 shares release their latest results. Some of these results have gone down well with investors and some have been received less enthusiastically. Three ASX 200 shares that are ma...

MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended 31 December 2022. All figures are in AU$ unless otherwise...

A three-week retreat in Australian shares looks set to continue this morning following falls on Wall Street after a rebound in inflation sharpened the risk of a return to jumbo interest rate hikes.   The S&P/ASX 200 will open 51 poin...

Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal...

Highlights A new 100-day high for ASX 200 was noted at market close on 1 February 2023. The ASX 200 was up, gaining 0.33% to 7,501.70. Over the past five days, ASX 200 has gained 0.45%. Top performers of the day included Flight Centr...

ASX health stocks rise 4.6% this week with positive signs of being back in favour Volpara soars after announcing its first net cash flow positive quarter Morgans basket of healthcare stock picks for 2023 faring well,  all up YTD Healthca...

The S&P/ASX 200 Index (ASX: XJO) wobbled in and out of the green on Wednesday before ultimately closing 0.1% higher at 7,393.4 points. Providing the biggest boost was the tech sector. The S&P/ASX 200 Information Technology Index (A...

The share market inched to a new eight-and-a-half-month high as a strong start to the year continued. The S&P/ASX 200 rose seven points or 0.1 per cent to 7393.4. Buying in the closing auction helped avert the first back-to-back loss...

The ASX closed flat on Wednesday Local investors are closely watching earnings reports in both the US and Australia EU to release inflation report tonight   The ASX 200 was subdued on Wednesday as investors weighed earnings results in the...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.1% to 7,396.1 points. Four ASX shares that are climbing more than most today are listed below...

Australian shares marked time for a second day as a mixed night on Wall Street gave investors few reasons to add to positions at an eight-month high. The S&P/ASX 200 nudged up seven points or 0.1 per cent by mid-session. Healthcar...

MELBOURNE, Australia, Jan. 18, 2023 /PRNewswire/ — 18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarte...

It’s a good day to own S&P/ASX 200 Index (ASX: XJO) biotech share Telix Pharmaceuticals Ltd (ASX: TLX). The company just revealed it has surpassed a major milestone towards profitability – positive cash flow. The Telix share price...

World Overnight SPI Overnight 7348.00 – 21.00 – 0.28% S&P ASX 200 7386.30 – 1.90 – 0.03% S&P500 3990.97 – 8.12 – 0.20% Nasdaq Comp 11095.11 + 15.96 0.14% DJIA 33910.85 – 391.76 – 1.14% S&P500 VIX 19.36 – 0.13 – 0.6...

ASX health stocks rise 0.8% this week as smaller names in sector show signs of being back in favour Volpara signs five 5-year contracts worth more than US$7.8 million in Total Contract Value Mach 7 continues its 2023 recovery after announc...

ShareCafeAlmost all sectors lower despite signs of optimism in the US: ASX down 0.3% at noon by Peter Milios   Overnight Chris Zaccarelli, Chief Investing Officer at the Independent Advisor Alliance, stated, “Today is another one of those d...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end its winning streak. At the time of writing, the benchmark index is down 0.2% to 7,137.1 points. Four ASX shares that are falling more than most today are listed...

The share market sealed its longest win run since early November with a fourth straight rise following strong gains on Wall Street as buyers bet on a soft landing for the US economy. The S&P/ASX 200 trimmed its advance as iron ore pr...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decent gain. At the time of writing, the benchmark index is up 0.55% to 7,148.9 points. Four ASX shares that have failed to follow the market hi...

Aussie shares hit a three-week high amid optimism about cooling inflation and China reopening. The S&P/ASX 200 rallied 44 points or 0.62 per cent by mid-session. The advance put the Australian benchmark on track for a fourth straight...

MELBOURNE, Australia, Jan. 9, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9 – 12 January) in San Francisco. As pa...

The share market snapped a run of four straight weekly declines following reports China may relax restrictions on property developers. The S&P/ASX 200 rallied 46 points or 0.65 per cent this afternoon to its third straight gain of th...

Resource stocks steered the ASX towards a third day of gains and a winning week to start 2023 despite pressure on Wall Street. The S&P/ASX 200 climbed 35 points or 0.5 per cent by mid-session. The heavily-weighted materials sector...

ASX 200 benchmark climbs 1.5% during an otherwise super-quiet day Tesla dives 12.2% and Apple slips back under US$2T market cap Extra-special bonus: The greatest sporting achievement we’re gonna see all year   Welcome to the end of the fi...

The S&P/ASX 200 Index (ASX: XJO) recovered from Tuesday’s fall today, lifting 1.63% to close at 7,059.2 points. Its gains came despite a rough night’s trade on Wall Street. The Dow Jones Industrial Average Index (DJX: .DJI) traded...

The ASX had its first positive day of gains in 2023 Tesla could still be overpriced despite a 70% fall – expert US Fed meeting minutes due out tonight   The ASX recorded its first day of gains for the year as financial and tech stocks led...

A new year got off to a challenging start with Australian stocks at eight-week lows as a month-long retreat continued in the wake of soft economic signals from major trading partner China.   The S&P/ASX 200 slumped 92.5 points or 1.3...

If you’re interested in adding some healthcare sector exposure to your portfolio, then it could be worth taking a look at what Bell Potter is recommending. It has named its top picks in the healthcare sector for 2023 and the two ASX heal...

The share market slumped to an eight-week low as signs of a sharp slowdown in major trading partner China offset positive leads from European stocks. At the halfway mark, the S&P/ASX 200 was down 127 points or 1.81 per cent after a b...